Breaking News

Otsuka Acquires Rights to Eisai’s Dacogen

March 31, 2014

Gains development and commercialization rights in the U.S., Canada and Japan

Eisai, Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., has sold the rights to DACOGEN (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd. DACOGEN is approved for treatment of patients with myelodysplastic syndromes
 
Through an exclusive worldwide license, Otsuka gains full development and commercialization rights for the product in the former Eisai territories of the U.S., Canada and Japan. Eisai will retain its rights for DACOGEN in Mexico. Otsuka will also gain the patent for Eisai’s metabolic enzyme inhibitor E7727.
 
Eisai's marketing rights for DACOGEN originate from a worldwide license from Astex Pharmaceuticals, Inc., which was acquired by Otsuka in October 2013.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers